Posted by Michael Wonder on 28 Nov 2023
Aldeyra Therapeutics receives complete response letter from the US FDA for the reproxalap new drug application for the treatment of dry eye disease
27 November 2023 - Additional trial required to demonstrate positive effect on the treatment of ocular symptoms in dry eye disease.
Aldeyra Therapeutics today announced receipt of a complete response letter from the US FDA for the new drug application of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.
